Kamada Announces Q2 and H1 2025 Financial Results on August 13, 2025.
PorAinvest
jueves, 7 de agosto de 2025, 7:14 pm ET1 min de lectura
KMDA--
Kamada Ltd. specializes in rare and serious conditions through plasma-derived products and is a leader in the specialty plasma-derived therapies field. The company's strategy focuses on driving profitable growth through four primary growth pillars: organic growth from commercial activities, securing new business development opportunities, expanding plasma collection operations, and advancing product candidate development [2].
Investors and financial professionals are encouraged to participate in the conference call to gain insights into Kamada Ltd.'s financial performance and strategic direction for the year. The conference call can be accessed by dialing 1-877-413-7208 (from within the U.S.), 1-809-406-247 (from Israel), or 1-201-689-8555 (International) using the conference I.D. 13754604. The call will also be webcast live on the internet at: https://viavid.webcasts.com/starthere.jsp?ei=1726126&tp_key=61b4d50ef5 [3].
References:
[1] https://www.stocktitan.net/news/KMDA/kamada-to-announce-second-quarter-and-first-half-ended-june-30-2025-eqat81hr403r.html
[2] https://www.biospace.com/press-releases/kamada-to-announce-second-quarter-and-first-half-ended-june-30-2025-financial-results-on-august-13-2025
[3] https://www.kamada.com/news/kamada-to-announce-second-quarter-and-first-half-ended-june-30-2025-financial-results-on-august-13-2025/
Kamada Ltd. will release its Q2 and H1 2025 financial results on August 13, 2025, prior to U.S. market opening. A conference call for investors will be held at 8:30 AM ET on the same day, with access via phone or webcast. The company aims to enhance its product portfolio through collaborations and acquisitions, and is focused on commercialization, product lifecycle management, and expanding plasma collection operations in the U.S.
Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial-stage global biopharmaceutical company, will release its Q2 and H1 2025 financial results on August 13, 2025, prior to the U.S. market open. The company will host an investment community conference call at 8:30 AM ET on the same day to discuss these results and take questions from shareholders and other interested parties [1].Kamada Ltd. specializes in rare and serious conditions through plasma-derived products and is a leader in the specialty plasma-derived therapies field. The company's strategy focuses on driving profitable growth through four primary growth pillars: organic growth from commercial activities, securing new business development opportunities, expanding plasma collection operations, and advancing product candidate development [2].
Investors and financial professionals are encouraged to participate in the conference call to gain insights into Kamada Ltd.'s financial performance and strategic direction for the year. The conference call can be accessed by dialing 1-877-413-7208 (from within the U.S.), 1-809-406-247 (from Israel), or 1-201-689-8555 (International) using the conference I.D. 13754604. The call will also be webcast live on the internet at: https://viavid.webcasts.com/starthere.jsp?ei=1726126&tp_key=61b4d50ef5 [3].
References:
[1] https://www.stocktitan.net/news/KMDA/kamada-to-announce-second-quarter-and-first-half-ended-june-30-2025-eqat81hr403r.html
[2] https://www.biospace.com/press-releases/kamada-to-announce-second-quarter-and-first-half-ended-june-30-2025-financial-results-on-august-13-2025
[3] https://www.kamada.com/news/kamada-to-announce-second-quarter-and-first-half-ended-june-30-2025-financial-results-on-august-13-2025/

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios